Amgen Rallies 10%+ After Hours on Q1 Earnings and Revenue Beats, Plus Well-Received Full-Year Guidance
Amgen Rallies 10%+ After Hours on Q1 Earnings and Revenue Beats, Plus Well-Received Full-Year Guidance
quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33 percent. By Jerry Kronenberg | Moomoo News
作者：杰里·克罗嫩伯格 | Moomoo 新闻
$Amgen (AMGN.US)$ rose more than 10% after hours Thursday after the pharma giant beat analyst estimates for Q1 earnings and revenues and guided full-year results to potentially exceed analysts’ forecasts.
$安进 (AMGN.US)$ 周四盘后上涨了10％以上，此前这家制药巨头超过了分析师对第一季度收益和收入的预期，并指导全年业绩可能超过分析师的预期。
AMGN gained 11.7% to $311 shortly before 5:30 p.m. ET after the firm reported $3.96 in Q1 earnings per share, reportedly beating analysts’ $3.87 consensus forecast.
美国东部时间下午5点30分前不久，AMGN上涨11.7％，至311美元，此前该公司公布的第一季度每股收益为3.96美元，据报道超过了分析师的3.87美元。
quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33 percent.
季度每股收益为3.96美元，比分析师普遍预期的3.87美元高出2.33％。
Sales totaled $7.447 billion, exceeding the $7.436 billion consensus among analysts and rising some 22% from the $6.105 billion Amgen recorded in the same period last year.
总销售额为74.47亿美元，超过了分析师共识的74.36亿美元，较去年同期安进的61.05亿美元增长了约22％。
AMGN also guided full-year earnings per share to a range of $19 to $20.20 on $32.5 billion to $33.8 billion in revenues. The range’s upper end would exceed analysts’ reported consensus forecast of $19.53 in full-year EPS and $32.9 billion of revenues.
AMGN还将全年每股收益定在19美元至20.20美元之间，收入为325亿美元至338亿美元。该区间的上限将超过分析师报告的共识预测，即全年每股收益19.53美元，收入为329亿美元。
Meanwhile, Amgen reportedly said in its conference call that it’s giving up on developing a pill form of weight-loss drugs that would compete with red-hot Ozempic and Wegovy, which users must inject with a syringe. Amgen rival $NOVO NORDISK A/S (NONOF.US)$ developed Ozempic and Wegovy.
同时，据报道，安进在电话会议上表示，它正在放弃开发一种药丸形式的减肥药物，这种药物将与炙手可热的Ozempic和Wegovy竞争，使用者必须用注射器注射。安进的竞争对手 $NOVO NORDISK A/S (NONOF.US)$ 开发了 Ozempic 和 Wegovy。
Still, Amgen reportedly said it plans to continue developing its own injectable weight-loss drug to take on those competitors.
尽管如此，据报道，安进表示计划继续开发自己的可注射减肥药物，以对抗这些竞争对手。